---
title: A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
nct_id: NCT01237171
overall_status: WITHDRAWN
sponsor: IsoRay Medical, Inc.
study_type: OBSERVATIONAL
primary_condition: NSCLC
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01237171.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01237171"
ct_last_update_post_date: 2021-03-30
last_seen_at: "2026-05-12T07:21:32.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer

**Official Title:** Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC

**NCT ID:** [NCT01237171](https://clinicaltrials.gov/study/NCT01237171)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Study never moved past ideation phase
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** IsoRay Medical, Inc.
- **Conditions:** NSCLC, Non Small Cell Lung Cancer
- **Start Date:** 2010-11
- **Completion Date:** 2010-11
- **CT.gov Last Update:** 2021-03-30

## Brief Summary

For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer. For some patients, the removal of a lobe of lung may leave too little lung behind for easy breathing. For some of these patients, it may be possible to perform a smaller-scale surgery ("sub-lobar resection") and place a radioactive implant behind to prevent the cancer from growing back. This study will see how these patients do in terms of controlling their disease treated with a radioactive implant called Cesium-131.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patients must have suspicious lung nodule for clinical stage I/recurrent non-small cell Lung Cancer
2. Mass Tumor size \< 7 cm
3. Patient must have a CT scan of the chest with upper abdomen within 90 days prior to date of pre-registration.
4. Patient must have ECOG/Zubrod performance status 0,1, or 2.

Exclusion Criteria:

1. Patient has already received high dose radiation to the area
2. Cancerous nodule is very close to the esophagus or spinal cord, thereby increasing the risk of radiation treatment
3. Pregnancy or unwillingness to practice a form of birth control (i.e. abstinence, oral contraceptives, etc.)
```

## Arms

- **Sub-lobar resection with Cesium-131** — All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.

## Interventions

- **Cesium-131 Brachytherapy Seed** (RADIATION) — 85 Gray Dose

## Primary Outcomes

- **Local Recurrence** _(time frame: 3 Years)_ — Cancer regrowth in the area where it was surgically removed

## Secondary Outcomes

- **Quality of Life** _(time frame: 2 years)_

## Locations (1)

- Weill Cornell Medical College, New York, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.weill cornell medical college|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01237171.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01237171*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*